Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Trial of D2C7-IT in Combination With Atezolizumab in Recurrent WHO Grade IV Malignant Glioma

NCT04160494 is registered in ClinicalTrials.gov with Darell Bigner as lead sponsor.

NCT NCT04160494
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04160494 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Trial of D2C7-IT in Combination With Atezolizumab in Recurrent WHO Grade IV Malignant Glioma
Lead sponsor
Darell Bigner
Phase
Phase 1
Overall status
Completed
Start date
February 25, 2020
Completion date
June 11, 2026
Enrollment
14 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

malignant glioma